Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc. has announced that its Venowave VW5 device received a permanent HCPCS code from the Centers for Medicare and Medicaid Services, enabling reimbursement for patients. The device, addressing a range of circulatory issues including DVT, now offers both purchase and rental options with capped reimbursement rates. This marks a significant advancement for the company, which aligns with the growing market for DVT treatments projected to reach $1.5 billion by 2032.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
